Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Two Studies Derived from Quell Health Cloud to be Presented at Upcoming PAINWeek National Conference
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO) today reported that it will present two scientific posters at the upcoming PAINWeek national conference to be held in Las Vegas, NV, September 5-9. Both studies leveraged the Quell ® Health Cloud, which connects with the Quell
View HTML
Toggle Summary NeuroMetrix Teams Up with U.S. Pain Foundation to Raise Awareness of Chronic Pain
WALTHAM, Mass. --(BUSINESS WIRE)-- In recognition of Pain Awareness Month this September, NeuroMetrix, Inc. (Nasdaq: NURO) is partnering with the U.S. Pain Foundation , a nonprofit organization dedicated to serving those who live with pain conditions and their providers, to raise awareness of the
View HTML
Toggle Summary NeuroMetrix Announces Issuance of New U.S. Patent for Automated Control of Quell Therapy During Sleep
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,731,126. The patent covers novel technology whereby the Quell ® device automatically modulates therapeutic neurostimulation based on the user's
View HTML
Toggle Summary NeuroMetrix Announces DPNCheck Distribution Agreement with Fukuda Denshi in Japan
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today reported an agreement with Fukuda Denshi for DPNCheck ® distribution in Japan . DPNCheck is NeuroMetrix' rapid, accurate, and quantitative point-of-care test to detect diabetic peripheral neuropathy.
View HTML
Toggle Summary NeuroMetrix Announces Shipment of 100,000th Quell Device Since Launch in 2015
BOSTON --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO) reported today that it had shipped its 100,000 th  Quell ® wearable device for treatment of chronic pain since commercial launch in mid-2015. Quell device shipments have posted growth in each of the eight sequential quarters that it has
View HTML
Toggle Summary NeuroMetrix Reports Q2 2017 Financial Results
Revenue of $4.3M is up 63% year-over-year Quell device shipments of 20.1K and electrode reorders of 30.7K represent new quarterly highs DPNCheck revenue of $0.8 million is up 78% year-over-year WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for 2017 Second Quarter Financial Results Conference Call
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (NASDAQ:NURO) announced today that it plans to issue its 2017 second quarter financial results before the opening of the market on Thursday July 20, 2017. The Company will host a conference call at 8:00 a.m., Eastern Time on July 20, 2017 to
View HTML
Toggle Summary NeuroMetrix Announces $7.0 Million Private Placement of Preferred Stock
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (NASDAQ: NURO) announced today that it has entered into a definitive securities purchase agreement with a healthcare dedicated institutional investor in connection with a private placement of 7,000 shares of Series F convertible preferred stock
View HTML
Toggle Summary NeuroMetrix Reports Promotion of Michael MacDonald to Senior Vice President and General Manager of Diagnostics
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO) today reported that Michael MacDonald has been promoted to SVP and General Manager of Diagnostics. In this role, Mr. MacDonald will oversee the Company's diagnostic products which include DPNCheck ® and ADVANCE™. Mr.
View HTML
Toggle Summary NeuroMetrix Provides Update on Quell Health Cloud Including Promotion of Dr. Xuan Kong to Chief Data Scientist
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO) today provided an update on its data science initiative and the related Quell ® Health Cloud. Data science consists of the development of large cloud databases and the use of powerful analytical tools such as machine learning and
View HTML